These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
397 related articles for article (PubMed ID: 32226538)
1. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis. Zhang Z; Yao Y; Yuan Q; Lu C; Zhang X; Yuan J; Hou K; Zhang C; Du Z; Gao X; Chen X Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538 [No Abstract] [Full Text] [Related]
2. Germacrone alleviates breast cancer-associated osteolysis by inhibiting osteoclastogenesis via inhibition of MAPK/NF-κB signaling pathways. Lin Z; Yang Y; Liu T; Wu Z; Zhang X; Yang J Phytother Res; 2024 Jun; 38(6):2860-2874. PubMed ID: 38558446 [TBL] [Abstract][Full Text] [Related]
3. Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor. Chen Y; Zheng J; Mo L; Chen F; Li R; Wang Y; Liang Q; Chen Z; Dai W; Chen L; Yan P; Zhou H; Li X Phytomedicine; 2024 Jul; 129():155688. PubMed ID: 38728920 [TBL] [Abstract][Full Text] [Related]
4. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment. Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935 [TBL] [Abstract][Full Text] [Related]
5. Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway. Jiang W; Rixiati Y; Huang H; Shi Y; Huang C; Jiao B Cancer Med; 2020 Nov; 9(21):8173-8185. PubMed ID: 32976685 [TBL] [Abstract][Full Text] [Related]
6. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling. Sung B; Oyajobi B; Aggarwal BB Mol Cancer Ther; 2012 Feb; 11(2):350-9. PubMed ID: 22090419 [TBL] [Abstract][Full Text] [Related]
7. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315 [TBL] [Abstract][Full Text] [Related]
8. Artemisinin inhibits breast cancer-induced osteolysis by inhibiting osteoclast formation and breast cancer cell proliferation. Li J; Feng W; Lu H; Wei Y; Ma S; Wei L; Liu Q; Zhao J; Wei Q; Yao J J Cell Physiol; 2019 Aug; 234(8):12663-12675. PubMed ID: 30536376 [TBL] [Abstract][Full Text] [Related]
10. The role played by ailanthone in inhibiting bone metastasis of breast cancer by regulating tumor-bone microenvironment through the RANKL-dependent pathway. Wang Y; Zhong Z; Ma M; Zhao Y; Zhang C; Qian Z; Wang B Front Pharmacol; 2022; 13():1081978. PubMed ID: 36686653 [No Abstract] [Full Text] [Related]
11. Gold Clusters Prevent Inflammation-Induced Bone Erosion through Inhibiting the Activation of NF-κB Pathway. Yuan Q; Gao F; Yao Y; Cai P; Zhang X; Yuan J; Hou K; Gao L; Ren X; Gao X Theranostics; 2019; 9(7):1825-1836. PubMed ID: 31037141 [TBL] [Abstract][Full Text] [Related]
12. Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways. Wang H; Shen W; Hu X; Zhang Y; Zhuo Y; Li T; Mei F; Li X; Xiao L; Chu T Breast Cancer Res Treat; 2015 Feb; 149(3):705-14. PubMed ID: 25667102 [TBL] [Abstract][Full Text] [Related]
13. IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis. Liang M; Ma Q; Ding N; Luo F; Bai Y; Kang F; Gong X; Dong R; Dai J; Dai Q; Dou C; Dong S Cell Death Dis; 2019 Apr; 10(5):353. PubMed ID: 31040267 [TBL] [Abstract][Full Text] [Related]
14. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss. Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665 [TBL] [Abstract][Full Text] [Related]
15. Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression. Liu Y; Zhang RX; Yuan W; Chen HQ; Tian DD; Li H; Jiang X; Deng ZL; Wang Y Cell Physiol Biochem; 2018; 45(5):1759-1771. PubMed ID: 29495003 [TBL] [Abstract][Full Text] [Related]
16. Polyphyllin VII protects from breast cancer-induced osteolysis by suppressing osteoclastogenesis via c-Fos/NFATc1 signaling. Yang Q; Guo J; Zheng J; Chen Y; Zou B; Li R; Ding Z; Wang Y; Li L; Chen Z; Mo L; Liang Q; Chen F; Li X Int Immunopharmacol; 2023 Jul; 120():110316. PubMed ID: 37253315 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis. Marino S; Bishop RT; Mollat P; Idris AI Calcif Tissue Int; 2018 Aug; 103(2):206-216. PubMed ID: 29455416 [TBL] [Abstract][Full Text] [Related]
18. CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis. Li X; Liang Y; Lian C; Peng F; Xiao Y; He Y; Ma C; Wang Y; Zhang P; Deng Y; Su Y; Luo C; Kong X; Yang Q; Liu T; Hu G Theranostics; 2021; 11(20):9821-9832. PubMed ID: 34815788 [No Abstract] [Full Text] [Related]
19. Rifampin suppresses osteoclastogenesis and titanium particle-induced osteolysis via modulating RANKL signaling pathways. Zhu L; Kang H; Guo CA; Fan WS; Wang YM; Deng LF; Yan ZQ Biochem Biophys Res Commun; 2017 Feb; 484(1):64-70. PubMed ID: 28108285 [TBL] [Abstract][Full Text] [Related]
20. Sinomenine inhibits osteolysis in breast cancer by reducing IL-8/CXCR1 and c-Fos/NFATc1 signaling. Zhang Y; Zou B; Tan Y; Su J; Wang Y; Xu J; Tao L; Zhou H; Liu L; Li X Pharmacol Res; 2019 Apr; 142():140-150. PubMed ID: 30797069 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]